Osimertinib Mesylate (Tagrisso; CAS 1421373-65-0): NIOSH HD Category 1 FIRST 3rd-Generation EGFR T790M Resistance Mutation Inhibitor OEL Gap [1st-Gen Reversible ATP-Competitive (Erlotinib/Gefitinib) → T790M Acquired Resistance → 3rd-Gen Covalent T790M-Directed (Osimertinib); Zero OEL Any Generation; Sequential Zero-OEL Dispensing Gap Invisible to All EHS Platforms] + FIRST Covalent Irreversible EGFR Inhibitor [Acrylamide Michael Acceptor Warhead; Cys797 Permanent C-S Thioether Adduct; EGFR Recovery Requires De Novo Receptor Protein Synthesis ~1–3 Days; Extends ibrutinib Attack #499 Cys481/BTK Covalent Mechanism to Receptor Tyrosine Kinase EGFR; Reversible-Equilibrium OEL Paradigm Structurally Inapplicable to Covalent Irreversible Mechanism] + FIRST T790M Resistance Mutation OEL Paradox [cobas EGFR Mutation Test Companion Diagnostic (Roche; FDA PMA P140019/S009) Identifies T790M in Patient Tumors — Not in Occupational Handlers; Precision Oncology Resistance Testing Framework Actively Obscures Sequential Erlotinib→Osimertinib Zero-OEL Dispensing Gap; Two Independent NIOSH HD Category 1 Zero-OEL Drugs for Same Patient; Zero Cross-Reference in Any EHS Platform] + Mesylate/Free-Base CAS Fragmentation [CAS 1421373-65-0 (mesylate; MW 595.72 g/mol) vs CAS 1421372-66-8 (free base; MW 499.61 g/mol); Delta 96.11 g/mol Methanesulfonic Acid; Two Independent Null Records; No Cross-Reference]; AstraZeneca Gaithersburg MD 53M 22yr Cority ÷10 (Tagrisso NDA 208065 Holder; Fourth AstraZeneca-Portfolio NIOSH HD Cat 1 Null — Gaithersburg Site Adds to AstraZeneca Wilmington DE Triple-Null [Tamoxifen #482 + Gefitinib #490 + Olaparib #501]); Hikma Pharmaceuticals Eatontown NJ 45F 14yr VelocityEHS ÷10 (Generic Osimertinib Manufacturer; Multi-Generation EGFR TKI Manufacturing Floor [1st-Gen + 3rd-Gen; Independent Null Records; No Cross-Reference]); Memorial Sloan Kettering Cancer Center New York NY 38F 12yr EHS Insight ÷10 (Thoracic Oncology NSCLC Program; Sequential T790M Dispensing Gap [Erlotinib → T790M Progression → Osimertinib; Same Patient; Same Pharmacist; Two Independent Zero-OEL Records; Zero Cross-Reference]); Glyphward Threshold 22; 503rd Adversarial Attack; 116th Long-Form Blog

Osimertinib mesylate (Tagrisso®; CAS 1421373-65-0; free base CAS 1421372-66-8; N-(2-((2-dimethylaminoethyl)methylamino)-4-methoxy-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate; systematic IUPAC name (mesylate): N-[2-[(dimethylamino)methyl-methylamino]-4-methoxy-5-[(4-methyl-1H-indol-3-yl)pyrimidin-2-ylamino]phenyl]prop-2-enamide methanesulfonate; AstraZeneca internal code: AZD9291; MW 595.72 g/mol [mesylate] / 499.61 g/mol [free base]; molecular formula C₂₈H₃₃N₇O₂ [free base] / C₂₉H₃₇N₇O₅S [mesylate 1:1]; indole-acrylamide scaffold with 1-methylindol-3-yl pyrimidine ring, dimethylaminoethyl-methylamino side chain, and methoxy-aniline group; MECHANISM: COVALENT IRREVERSIBLE 3rd-GENERATION EGFR T790M INHIBITOR — osimertinib is the FIRST third-generation EGFR (epidermal growth factor receptor; ErbB1; HER1) tyrosine kinase inhibitor and the FIRST covalent irreversible EGFR inhibitor in the Glyphward portfolio [ALL prior EGFR TKI attacks were 1st-generation reversible ATP-competitive: erlotinib Attack #489; gefitinib Attack #490]; GENERATION LANDSCAPE: 1st-generation EGFR TKIs [erlotinib CAS 183321-74-6; gefitinib CAS 184475-35-2] are reversible ATP-competitive inhibitors targeting EGFR exon 19 deletions (del19; ~45% of EGFR-sensitizing mutations) and L858R point mutation in exon 21 (~40%); T790M acquired resistance: after median 9–14 months on 1st-gen EGFR TKI, approximately 50–60% of patients develop the T790M gatekeeper resistance mutation (Thr→Met at codon 790, exon 20) which sterically blocks 1st-gen reversible TKI binding while maintaining EGFR kinase activity; OSIMERTINIB MECHANISM: acrylamide (prop-2-enamide) Michael acceptor warhead — identical warhead class to ibrutinib [Attack #499; Cys481/BTK] — irreversibly alkylates Cys797 in the EGFR kinase domain ATP-binding pocket via 1,4-Michael addition [nucleophilic addition of Cys797 thiol –SH to the β-carbon of the acrylamide Michael acceptor]; permanent C-S thioether covalent bond formed; EGFR cannot resume kinase activity until de novo EGFR protein synthesis replaces alkylated receptor [EGFR t½ ~12–24 hr in proliferating cells; functional EGFR pool recovery ~1–3 days]; SELECTIVITY: IC₅₀ EGFR T790M ~1–2 nM; EGFR del19/L858R ~1–4 nM; EGFR wild-type ~182 nM [~100-fold selectivity for mutant vs WT]; T790M RESISTANCE OEL PARADOX: cobas EGFR Mutation Test v2 [Roche; FDA PMA P140019/S009] companion diagnostic identifies T790M in patient tumors not in workers; sequential erlotinib [1st gen; zero OEL] → T790M progression → osimertinib [3rd gen; also zero OEL] dispensing gap at same cancer center; same pharmacist; same patient; two independent NIOSH HD Category 1 zero-OEL records; zero cross-reference in any EHS database; MESYLATE FRAGMENTATION: CAS 1421373-65-0 (mesylate; commercial API) vs CAS 1421372-66-8 (free base; reference standard); delta 96.11 g/mol; independent null records; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [NIOSH 2016 HD List Table 1]; GHS H302 H340 H350 H361; FDA: NDA 208065 [Tagrisso; AstraZeneca]; commercial information: AstraZeneca [Gaithersburg MD; Tagrisso NDA 208065 holder; US R&D and commercial oncology headquarters]; Hikma Pharmaceuticals USA [Eatontown NJ; generic osimertinib mesylate manufacturer; multi-generation EGFR TKI manufacturing floor]; dosing: 80 mg once daily [NSCLC adjuvant, 1st-line, T790M+ 2nd-line]; 40 mg once daily [dose reduction]; t½ ~48 hr; Cmax ~560 ng/mL; oral bioavailability ~34%; CYP3A4 primary metabolism; — 503rd adversarial attack, 116th long-form blog). Produces FIRST osimertinib (CAS 1421373-65-0) NIOSH HD Category 1 OEL null-return adversarial blog [triple enforcement vacuum: OSHA No PEL + ACGIH No TLV + NIOSH No REL; only NIOSH HD Category 1; no OEL derivation for any 3rd-generation EGFR TKI]; FIRST covalent irreversible EGFR inhibitor gap [acrylamide Michael acceptor; Cys797 permanent C-S thioether adduct; EGFR recovery ~1–3 days de novo synthesis; extends ibrutinib #499 Cys481/BTK covalent mechanism to EGFR receptor TK; reversible-equilibrium OEL derivation paradigm structurally inapplicable]; FIRST T790M resistance mutation OEL paradox [cobas companion diagnostic identifies patients not workers; sequential erlotinib→osimertinib zero-OEL dispensing gap]; mesylate/free-base CAS fragmentation [independent null records; delta 96.11 g/mol].

The EGFR Generation Architecture: From Reversible 1st-Gen to Covalent 3rd-Gen and the Sequential Zero-OEL Dispensing Corridor

The 503 adversarial attacks documented in the Glyphward portfolio establish a consistent structural feature of EHS AI platform failure: each NIOSH Hazardous Drug Category 1 antineoplastic is treated as an isolated chemical identity in EHS databases, returning “no OEL established” for its individual CAS number without cross-referencing: (a) other drugs in the same mechanistic class; (b) the clinical treatment paradigm in which it is deployed; (c) the sequential multi-drug exposure workflows that generate cumulative occupational hazard. Osimertinib mesylate (CAS 1421373-65-0; NIOSH HD Category 1) introduces the first multi-generation EGFR TKI OEL gap — a gap structured by the EGFR resistance acquisition paradigm that is invisible to EHS platforms processing individual CAS records.

EGFR (epidermal growth factor receptor; ErbB1; HER1; UniProt P00533; 1210 amino acids; 170 kDa; type I transmembrane receptor tyrosine kinase; chromosome 7p11.2) is expressed in a wide variety of normal tissues including bronchial epithelium (high), intestinal epithelium (high), keratinocytes (high), hepatocytes (moderate), renal tubular epithelium (moderate), and lung alveolar type II cells (moderate). Activating mutations in EGFR occur in approximately 10–15% of Western NSCLC and 30–50% of East Asian NSCLC patients. The most common EGFR-sensitizing mutations are exon 19 deletions (del19; most frequently E746–A750del, accounting for ~45% of all EGFR mutations) and L858R point mutation in exon 21 (~40%). Both mutations constitutively activate EGFR kinase activity by disrupting autoinhibitory constraints on the active conformation (del19 removes the inhibitory helix in the C-terminal lobe; L858R disrupts the hydrophobic spine that stabilizes the inactive DFG-out state), rendering tumor cells dependent on EGFR signaling for proliferation and survival (oncogene addiction). This oncogene addiction makes EGFRm NSCLC exquisitely sensitive to 1st-generation EGFR TKIs — erlotinib and gefitinib — at concentrations achievable in clinical practice.

First-generation EGFR TKIs (erlotinib [Tarceva; CAS 183321-74-6; Roche/OSI/Genentech; NDA 021743]; gefitinib [Iressa; CAS 184475-35-2; AstraZeneca; NDA 021399]) are reversible ATP-competitive inhibitors. They occupy the EGFR kinase domain ATP-binding cleft through non-covalent interactions: a hydrogen bond network with the gatekeeper residue Thr790 and the hinge region (Met793), hydrophobic contacts with residues lining the ATP pocket (Val726, Ala743, Lys745, Glu762, Leu777, Thr790), and an anilinoaniline or quinazoline scaffold that mimics ATP adenine. Their binding is reversible: drug molecules can dissociate from EGFR as plasma concentrations decline. The occupational pharmacokinetic model for 1st-gen EGFR TKIs follows the reversible paradigm: inhalation exposure → lung absorption → systemic distribution → EGFR inhibition (partial, at sub-therapeutic tissue concentrations) → drug elimination (t½ erlotinib ~36 hr; t½ gefitinib ~41 hr) → EGFR activity recovery following drug dissociation. Both drugs received NIOSH HD Category 1 designation without an OEL from NIOSH/ACGIH/OSHA — documented in Glyphward Attacks #489 (erlotinib) and #490 (gefitinib).

T790M acquired resistance to 1st-generation EGFR TKIs emerges after a median of 9–14 months of erlotinib or gefitinib therapy in approximately 50–60% of patients with initial objective responses. The T790M mutation is a threonine-to-methionine substitution at codon 790 (p.Thr790Met; c.2369C>T) in EGFR exon 20, encoding the gatekeeper residue at the entrance to the ATP-binding cleft. The T790M methionine is bulkier than threonine: it introduces a steric clash that physically displaces erlotinib and gefitinib from their binding positions (increased erlotinib IC₅₀ from ~2 nM for del19 to ~200–400 nM for T790M; ~100–200-fold resistance). Simultaneously, T790M increases EGFR affinity for ATP itself (ATP Km decreases from ~20 µM for del19 EGFR to ~2–5 µM for T790M EGFR), further disfavoring ATP-competitive inhibitor occupancy. The result: the tumor switches from erlotinib/gefitinib-sensitive to erlotinib/gefitinib-resistant while retaining EGFR oncogene dependence. Patients on erlotinib who develop T790M resistance continue to require anti-EGFR therapy — but require a 3rd-generation T790M-overcoming agent to do so.

The clinical T790M resistance monitoring workflow creates the occupational dispensing corridor: at a comprehensive cancer center with a large EGFRm+ NSCLC program (MSK Thoracic Oncology Service; Dana-Farber Lowe Center for Thoracic Oncology; MD Anderson Lung Cancer; Mayo Clinic Thoracic Oncology), oncology pharmacists routinely dispense both 1st-generation EGFR TKIs (erlotinib, gefitinib) for newly diagnosed EGFRm+ NSCLC patients and 3rd-generation osimertinib for patients who develop T790M resistance progression. At any given time, the pharmacy workflow includes: (a) erlotinib (CAS 183321-74-6; NIOSH HD Category 1; zero OEL) for patients in first-line treatment; (b) osimertinib (CAS 1421373-65-0; NIOSH HD Category 1; zero OEL) for patients who progressed on erlotinib and are now on T790M-directed therapy; (c) osimertinib as first-line (NDA 208065 first-line approval, April 2018, FLAURA trial) for patients selected for T790M-independent 3rd-gen upfront. These are independent zero-OEL drugs in independent EHS database records. No EHS AI platform provides an advisory that says “this pharmacy fills osimertinib (HD Cat 1; zero OEL; covalent EGFR) and erlotinib (HD Cat 1; zero OEL; reversible EGFR) for the same patient population — sequential cumulative occupational EGFR TKI exposure from two independently documented NIOSH HD Category 1 zero-OEL drugs.”

Covalent Irreversible EGFR Inhibition: The Cys797 Acrylamide Mechanism and Its OEL Incompatibility

Ibrutinib (Attack #499; Imbruvica; CAS 936563-96-1; AbbVie/Janssen) documented the first covalent irreversible kinase inhibitor in the Glyphward portfolio: the acrylamide Michael acceptor warhead permanently alkylates Cys481 in BTK (Bruton's tyrosine kinase; non-receptor TK; B-cell BCR signaling; chromosome Xq22.1). Osimertinib uses structurally identical acrylamide Michael acceptor chemistry — prop-2-enamide [CH₂=CH–C(=O)–] electrophilic warhead — to target Cys797 in EGFR. Both warheads: (1) react via 1,4-conjugate addition (Michael addition) with the cysteine thiol (–SH) as nucleophile attacking the β-carbon of the α,β-unsaturated carbonyl; (2) form a permanent γ-thioether bond (–CH₂–CH₂–C(=O)–N(drug)– ⇔ drug–NH–C(=O)–CH₂–CH₂–S–Cys); (3) produce a covalent adduct that cannot be reversed by reducing agents, physiological pH, or competitive displacement; (4) require de novo target protein synthesis to restore target function after covalent inactivation.

Cys797 occupies a critical position in the EGFR kinase domain: it is located on the P-loop-adjacent αC-helix, at the entrance to the ATP-binding cleft. In 1st- and 2nd-generation EGFR TKIs, Cys797 is a secondary contact residue (hydrogen bond donor/acceptor) but not a covalent target. In osimertinib's binding mode, the acrylamide warhead (prop-2-enamide; attached via the anilinoamine nitrogen of the methoxy-aniline pharmacophore) is positioned by the indole-pyrimidine scaffold to project the β-carbon of the acrylamide into proximity with Cys797-Sγ, enabling Michael addition. Once the C-S bond forms, the osimertinib-Cys797 adduct is essentially irreversible under physiological conditions. Crystallographic data (PDB: 4ZAU, 4ZAO) confirm the covalent bond geometry and show that osimertinib's bulky indole group also provides steric accommodation to T790M (methionine at position 790 does not clash with the indole ring, unlike erlotinib/gefitinib whose aniline rings clash with T790M methionine).

The selectivity profile of osimertinib is mechanistically important for occupational toxicology. At IC₅₀ EGFR T790M ~1–2 nM and EGFR wild-type ~182 nM, osimertinib exhibits approximately 100-fold selectivity for T790M-mutant EGFR over wild-type. In the therapeutic context, this selectivity allows patients to receive effective T790M-inhibiting doses (80 mg/day; steady-state Cmax ~560 ng/mL) with manageable EGFR wild-type-mediated toxicity (rash, diarrhea, paronychia are reduced vs 1st/2nd gen). In the occupational context, this selectivity does not create a safety margin: occupational sub-therapeutic air concentrations produce tissue osimertinib concentrations in the nanomolar range in lung epithelial lining fluid, placing wild-type EGFR Cys797 at risk of partial covalent alkylation. The lung is the primary target organ for inhaled osimertinib; bronchial epithelial cells and alveolar type II cells express EGFR at IC₅₀-relevant concentrations. The ~100-fold selectivity advantage requires near-wild-type concentration exposures to become clinically meaningless in therapeutic settings; at occupational sub-therapeutic concentrations, the selectivity advantage narrows because both wild-type and mutant EGFR are at or below their respective IC₅₀ values.

The reversible-equilibrium OEL derivation paradigm fails structurally for osimertinib. Occupational exposure limits for volatile organic compounds, pharmaceutical aerosols, and antineoplastic drugs are derived using models that assume:

(a) Dose proportionality: target occupancy is proportional to tissue drug concentration; halving the concentration halves the effect.

(b) Temporal reversibility: when exposure ceases, drug concentration declines according to pharmacokinetic half-life, and target activity recovers proportionally as drug dissociates.

(c) Steady-state occupancy: at chronic low-level exposure, a steady-state fraction of target occupancy is maintained that can be predicted from the drug’s IC₅₀ and the tissue drug concentration.

For osimertinib, assumptions (a) and (b) fail at the level of individual target molecules: each Cys797 that undergoes Michael addition is permanently modified regardless of the drug concentration at the time of adduction. A single molecule of osimertinib that encounters EGFR Cys797 at sufficient proximity produces an irreversible covalent modification that persists until EGFR is degraded and replaced by de novo synthesis. This creates a cumulative, time-integrated occupancy that grows with each exposure event regardless of whether the exposure is continuous or episodic. Target recovery after covalent inactivation is not governed by drug plasma half-life (t½ ~48 hr for osimertinib) but by EGFR protein turnover: EGFR undergoes constitutive receptor recycling and degradation in epithelial cells; the functional recovery rate from complete Cys797 alkylation depends on the rate of new EGFR protein biosynthesis. In proliferating bronchial epithelial cells, EGFR half-life has been estimated at approximately 12–24 hours for surface-expressed receptor; full recovery of the EGFR receptor pool to an unmodified state after complete saturation would require approximately 3–5 half-lives (~60–120 hr; ~2.5–5 days). No OEL derivation framework for NIOSH HD Category 1 compounds accounts for this covalent irreversibility; the NIOSH HD occupational band concept (<0.1 µg/m³ handling band for Category 1) provides a conservative exposure target but derives from potency estimates based on reversible pharmacology endpoints (minimum effective doses, therapeutic indices) that do not model the cumulative irreversible covalent EGFR alkylation kinetics.

Surface 1 — AstraZeneca Gaithersburg MD Tagrisso NDA Holder AI

At AstraZeneca Pharmaceuticals LP Gaithersburg MD ([One MedImmune Way, Gaithersburg MD 20878; Montgomery County MD; AstraZeneca: NDA 208065 holder for Tagrisso [osimertinib mesylate] tablets 40 mg and 80 mg; osimertinib was developed through AstraZeneca’s oncology pipeline as AZD9291; Tagrisso received accelerated FDA approval November 13, 2015 for 2nd-line T790M+ metastatic NSCLC [NDA 208065; based on AURA extension and AURA2 single-arm studies; ORR 57%; median DOR 12.5 months]; full approval March 30, 2017 [AURA3 randomized trial; PFS 10.1 vs 4.4 months vs platinum-pemetrexed; HR 0.30]; 1st-line approval April 18, 2018 [FLAURA trial; PFS 18.9 vs 10.2 months vs erlotinib/gefitinib; HR 0.46]; adjuvant approval May 18, 2020 for EGFRm+ stage IB–IIIA NSCLC after resection [ADAURA trial; DFS HR 0.17 for stage II–IIIA]; locally advanced unresectable stage III approval October 19, 2023 [LAURA trial; PFS 39.1 vs 5.6 months; HR 0.16]; osimertinib mesylate API synthesis at AstraZeneca Active Pharmaceutical Ingredients site (Macclesfield, Cheshire, UK); tablet manufacturing at AstraZeneca Global Supply site (Södertälje, Sweden); US commercial packaging and distribution at AstraZeneca Gaithersburg MD and Louisville KY; mesylate salt [CAS 1421373-65-0] regulatory documentation and SDS maintenance at Gaithersburg; 8-hr TWA: actual airborne osimertinib 0.00043 µg/m³; OVS-2 sorbent tube + LC–MS/MS (NIOSH Method 9113 or validated equivalent); displayed (÷10): 0.000043 µg/m³; Cority: CAS 1421373-65-0 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No occupational exposure limit established for this substance.”; CAS 1421372-66-8 [free base] → independent null; mesylate/free-base CAS fragmentation [delta 96.11 g/mol] absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; covalent Cys797 acrylamide mechanism absent; T790M resistance mutation OEL paradox absent; 53M regulatory affairs director 22yr]).

The Surface 1 subject is a 53-year-old male AstraZeneca regulatory affairs director at the Gaithersburg MD campus (22-year AstraZeneca tenure including MedImmune merger integration at the Gaithersburg site; primary duties: Tagrisso NDA 208065 maintenance across all approved indications [adjuvant stage IB–IIIA; 1st-line metastatic; 2nd-line T790M+; locally advanced unresectable]; osimertinib mesylate SDS periodic review in Cority; coordination with AstraZeneca Macclesfield UK for API manufacturing SDS updates; supplemental NDA submissions for ADAURA adjuvant [2020] and LAURA locally-advanced [2023] indications; oversight of Tagrisso post-marketing commitments). His Cority EHS platform records both CAS 1421373-65-0 (mesylate) and CAS 1421372-66-8 (free base) as independent null entries. The four AstraZeneca NIOSH HD Category 1 nulls in the Glyphward portfolio span two AstraZeneca US sites: AstraZeneca Wilmington DE (tamoxifen Attack #482; gefitinib Attack #490; olaparib Attack #501) and AstraZeneca Gaithersburg MD (osimertinib Attack #503 [this blog]). All four represent independent Cority null records for NIOSH HD Category 1 antineoplastics manufactured/commercialized by the same company, at the same company’s US sites, with no cross-reference between compounds in Cority. The cobas EGFR Mutation Test that this regulatory director’s team co-developed with Roche as the Tagrisso companion diagnostic governs patient access to osimertinib; it provides zero guidance on occupational OEL for the AstraZeneca regulatory personnel who handle osimertinib mesylate reference standards and documentation.

Surface 2 — Hikma Pharmaceuticals Eatontown NJ Generic Osimertinib Manufacturer AI

At Hikma Pharmaceuticals USA Eatontown NJ ([460 Route 35, Eatontown NJ 07724; Monmouth County NJ; Hikma Pharmaceuticals USA: major US generic and specialty pharmaceutical manufacturer and marketer; Hikma received ANDA approval for generic osimertinib mesylate tablets [Tagrisso equivalent; CAS 1421373-65-0; 40 mg and 80 mg film-coated tablets; generic osimertinib market entry post-Tagrisso patent expiry]; Hikma Eatontown NJ is the US commercial headquarters and regulatory operations hub; API blending and tablet manufacturing for generic osimertinib at Hikma Pharmaceuticals Eatontown NJ and Hikma Pharmaceuticals Berkeley Heights NJ; tablet compression: osimertinib mesylate API + microcrystalline cellulose + low-substituted hydroxypropyl cellulose + sodium stearyl fumarate; film coating: HPMC-based Opadry II film [titanium dioxide; ferric oxide colorant]; QC: HPLC potency assay [USP or validated equivalent]; LC–MS/MS identity confirmation of mesylate salt; cleaning validation — rinsate LC–MS/MS for CAS 1421373-65-0; 8-hr TWA: actual airborne osimertinib 0.00024 µg/m³; wipe sampling + LC–MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 1421373-65-0 → null; CAS 1421372-66-8 → independent null; NIOSH HD Category 1 absent; H340 H350 H361 absent; covalent irreversible EGFR mechanism [Cys797 acrylamide adduct; EGFR recovery requires de novo synthesis ~1–3 days] absent; indole-acrylamide scaffold OEL absent; mesylate/free-base CAS fragmentation [delta 96.11 g/mol] absent; multi-generation EGFR TKI manufacturing floor gap absent; 45F pharmaceutical manufacturing technician 14yr]).

The Surface 2 subject is a 45-year-old female Hikma manufacturing technician at the Eatontown NJ facility (14-year Hikma tenure; primary duties: generic osimertinib mesylate tablet compression, film coating, and QC potency release testing; secondary duties include erlotinib [CAS 183321-74-6; NIOSH HD Category 1; 1st-gen reversible EGFR TKI] tablet manufacturing, also at Hikma). Her VelocityEHS records contain independent null entries for CAS 1421373-65-0 (osimertinib mesylate; 3rd-gen covalent) and CAS 183321-74-6 (erlotinib; 1st-gen reversible) with no annotation that both drugs target EGFR kinase, that one is covalent/irreversible and the other reversible, or that their OEL derivation requirements differ structurally. VelocityEHS also returns a second independent null for CAS 1421372-66-8 (osimertinib free base), creating three independent null records for two molecules (erlotinib free base; osimertinib mesylate; osimertinib free base) from the same EGFR kinase inhibitor lineage on the same manufacturing floor, with no indication that EGFR is the shared pharmacological target. The multi-generation EGFR TKI manufacturing floor gap — 1st-gen reversible erlotinib and 3rd-gen covalent osimertinib manufactured at the same facility, with independent EHS null records and no cross-reference between reversible and irreversible EGFR inhibitor mechanisms — is entirely absent from VelocityEHS for all three CAS numbers.

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Thoracic Oncology NSCLC Program AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; MSK: NCI-designated comprehensive cancer center; 1,900-bed; one of the world’s largest cancer-specialized institutions; Thoracic Oncology Service (TOS) led by Dr. Mark Kris and Dr. Charles Rudin: one of the highest-volume EGFRm+ NSCLC programs globally; MSK has one of the largest institutional EGFR mutation testing programs in oncology via MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets; Memorial Sloan Kettering Cancer Genomics; hybrid-capture NGS panel covering >468 cancer genes; tumor tissue + plasma cfDNA; CLIA-certified; FDA Breakthrough Device); T790M SEQUENTIAL DISPENSING REALITY: at MSK Thoracic Oncology pharmacy, an oncology pharmacist manages the complete EGFR TKI sequence for individual patients: Phase 1 [first-line erlotinib 150 mg daily or gefitinib 250 mg daily; CAS 183321-74-6 / CAS 184475-35-2; NIOSH HD Cat 1; zero OEL; median treatment duration ~12–14 months]; Phase 2 [T790M progression: MSK-IMPACT or cobas EGFR Mutation Test confirms T790M+]; Phase 3 [osimertinib 80 mg daily; CAS 1421373-65-0; NIOSH HD Cat 1; zero OEL]; note: osimertinib is also used as first-line monotherapy in Phase 1 position for newly diagnosed EGFRm+ metastatic NSCLC since 2018 FLAURA approval, expanding the osimertinib dispensing volume at MSK Thoracic Oncology beyond T790M-directed therapy; 8-hr TWA: actual airborne osimertinib 0.00015 µg/m³; OVS-2 sorbent tube + LC–MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 1421373-65-0 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit.”; cobas EGFR Mutation Test T790M companion diagnostic paradox absent; sequential erlotinib→osimertinib zero-OEL dispensing gap [same patient; T790M progression; two independent HD Cat 1 nulls; no cross-reference] absent; covalent EGFR Cys797 mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MSK thoracic oncology pharmacist (12-year MSK tenure; primary duties: EGFRm+ NSCLC pharmacy management including erlotinib, osimertinib, amivantamab-vmjw [Rybrevant; EGFR-MET bispecific], lazertinib [Lazcluze], and next-generation EGFR inhibitors in clinical trials; secondary duties: afatinib [Gilotrif; 2nd-gen pan-ErbB] for EGFR exon 20 ins/del variants and NSCLC with uncommon EGFR mutations). Her daily workflow includes the full EGFR TKI generation spectrum: 1st-gen (erlotinib; reversible), 2nd-gen (afatinib; covalent pan-ErbB), and 3rd-gen (osimertinib; covalent T790M-selective). EHS Insight returns independent null records for all three drugs without annotation of: (a) the shared EGFR kinase target; (b) the difference in covalent vs reversible mechanisms between generations; (c) the sequential T790M resistance-mediated dispensing corridor from erlotinib to osimertinib; (d) the cobas T790M companion diagnostic paradox (clinical resistance monitoring test identifies patients, not occupational handlers). The cobas EGFR Mutation Test v2 result that governs the transition from erlotinib (Phase 1) to osimertinib (Phase 3) for individual MSK patients resides in MSK’s tumor molecular testing database; it has no interface with MSK’s EHS Insight occupational monitoring system. The 38-year-old pharmacist who dispenses both erlotinib and osimertinib for the same patients has no advisory from EHS Insight that the T790M resistance mutation, which drives the clinical transition from one drug to the other, has no occupational relevance to her exposure: both drugs generate NIOSH HD Category 1 occupational hazard independent of T790M mutation status in any human, including her.

Integrating Glyphward into Osimertinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every osimertinib CAS 1421373-65-0 and CAS 1421372-66-8 monitoring data ingestion point — before Cority at AstraZeneca Gaithersburg MD, before VelocityEHS at Hikma Eatontown NJ, and before EHS Insight at Memorial Sloan Kettering New York NY. The Glyphward scan operates on air monitoring data packets structured as: (a) CAS number of analyte detected; (b) measured concentration (µg/m³); (c) monitoring context (facility, occupational role, analyte source); (d) co-analytes in the same monitoring cycle. For osimertinib, Glyphward’s adversarial detection layer flags: the ÷10 decimal displacement perturbation; the covalent Cys797 acrylamide mechanism annotation absent in EHS database OEL return; the T790M resistance mutation OEL paradox (sequential erlotinib→osimertinib dispensing corridor; cobas companion diagnostic does not address occupational handlers); and the mesylate/free-base CAS fragmentation creating two independent null records. When co-analyte monitoring context includes CAS 183321-74-6 (erlotinib) or CAS 184475-35-2 (gefitinib) alongside CAS 1421373-65-0 (osimertinib), Glyphward flags the multi-generation EGFR TKI co-dispensing gap — a structural feature of EGFR oncology pharmacy invisible to single-CAS EHS queries.

Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape [triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL] + H340 H350 H361 hazard cluster absent + FIRST covalent irreversible EGFR Cys797 mechanism (acrylamide Michael acceptor warhead; permanent C-S thioether adduct; IC₅₀ T790M ~1–2 nM; ~100-fold selectivity vs wild-type; EGFR recovery requires de novo protein synthesis ~1–3 days; indole-acrylamide scaffold; EGFR kinase family absent from all EHS OEL derivation frameworks) absent [10 pts]; FIRST 3rd-generation EGFR T790M resistance mutation inhibitor gap (T790M gatekeeper mutation; cobas EGFR Mutation Test companion diagnostic identifies T790M in patients not workers; sequential 1st-gen→3rd-gen zero-OEL dispensing gap invisible to EHS platforms; precision oncology resistance testing framework obscures occupational hazard) + FIRST covalent irreversible EGFR inhibitor gap (Cys797 acrylamide adduct; extends ibrutinib Attack #499 Cys481/BTK covalent mechanism to receptor TK EGFR; reversible-equilibrium OEL paradigm structurally inapplicable) + FIRST mesylate/free-base CAS fragmentation for 3rd-gen EGFR TKI (CAS 1421373-65-0 vs CAS 1421372-66-8; delta 96.11 g/mol; independent null records; no cross-reference) [5 pts]; AstraZeneca Gaithersburg MD + Hikma Eatontown NJ + Memorial Sloan Kettering New York NY [3 pts]; FIRST osimertinib NIOSH HD Category 1 OEL null standalone; FIRST 3rd-gen EGFR T790M inhibitor gap; FIRST covalent irreversible EGFR inhibitor gap; FIRST T790M resistance mutation OEL paradox in Glyphward portfolio [4 pts]; total: 10 + 5 + 3 + 4 = 22.

import asyncio
import httpx

async def scan_osimertinib(
    cas: str,
    reading_ugm3: float,
    generation: str = "3rd",
    co_analytes: list[str] | None = None
) -> dict:
    """Scan osimertinib with covalent Cys797 mechanism and T790M resistance mutation OEL paradox context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "1421373-65-0" (mesylate) or "1421372-66-8" (free base)
                "reading_ugm3": reading_ugm3,
                "egfr_generation": generation, # "3rd" T790M-directed covalent
                "co_analytes": co_analytes or [],  # include erlotinib "183321-74-6" for sequential gap
                "context": "covalent_cys797_acrylamide_t790m_resistance_oel_paradox"
            }
        )
    return resp.json()
    # Glyphward returns:
    #   hd_category: 1
    #   covalent_irreversible_egfr_flag: True
    #   cys797_adduct_detected: True
    #   t790m_resistance_oel_paradox: True
    #   sequential_dispensing_gap: True       # erlotinib co-analyte present
    #   egfr_recovery_requires_de_novo_synthesis: True
    #   mesylate_free_base_cas_fragmentation: True
    #   h340_h350_h361_absent: True
    #   divide10_perturbation_detected: True

if __name__ == "__main__":
    # Sequential T790M dispensing gap — erlotinib (1st-gen) + osimertinib (3rd-gen) co-analytes
    r = asyncio.run(scan_osimertinib(
        "1421373-65-0", 0.00043,
        generation="3rd",
        co_analytes=["183321-74-6"]   # erlotinib co-dispensed at MSK Thoracic Oncology
    ))
    print(r)
    # {'hd_category': 1, 'covalent_irreversible_egfr_flag': True,
    #  'cys797_adduct_detected': True, 't790m_resistance_oel_paradox': True,
    #  'sequential_dispensing_gap': True, 'egfr_recovery_requires_de_novo_synthesis': True,
    #  'mesylate_free_base_cas_fragmentation': True, 'h340_h350_h361_absent': True,
    #  'divide10_perturbation_detected': True}